Exosome-mediated delivery of super-repressor IκBα alleviates inflammation and joint damages in rheumatoid arthritis
Authors:
Open Access
- 2 January 2024
- journal article
- research article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 26 (1) , 1-13
Abstract
Background: This study aims to investigate the potential anti-inflammatory effects of exosomes engineered to carry super-repressor IκB (Exo-srIκB), an exosome-based NF-κB inhibitor, in the context of RA. Methods: Peripheral blood mononuclear cells (PBMCs) and synovial fluid mononuclear cells (SFMCs) were collected from patients diagnosed with RA and treated with Exo-srIκB to test the therapeutic potential. Flow cytometry analysis was performed to assess the production of inflammatory cytokines (IL-17A and GM-CSF) by the cells. ELISA was utilized to measure the levels of TNF-α, IL-17A, IL-6, and GM-CSF. Arthritis was induced in SKG mice by intraperitoneal injection of curdlan. DBA/1 J mice were used in collagen-induced arthritis (CIA) experiments. After the development of arthritis, mice were injected with either Exo-Naïve (control exosome) or Exo-srIκB. Arthritis scores were recorded biweekly, and histological observations of the ankle joint were conducted using H&E and safranin-O staining. Additionally, bone erosion was evaluated using micro-CT imaging. Results: In the ex vivo study involving human PBMCs and SFMCs, treatment with Exo-srIκB demonstrated a notable reduction in inflammatory cytokines. Furthermore, in both the SKG and CIA models, Exo-srIκB treatment exhibited significant reductions in inflammation, cartilage destruction, and bone erosion within the joint tissues when compared to the Exo-Naive control group. Additionally, the radiographic score assessed through microCT showed a significant decrease compared to the Exo-Naive control group. Conclusion: Overall, these findings suggest that Exo-srIκB possesses anti-inflammatory properties in human RA cells and animal models, making it a promising therapeutic candidate for the treatment of RA.Keywords
Funding Information
- ILIAS Biologics fund (ILIAS fund - CNU, ILIAS fund - CNU)
This publication has 27 references indexed in Scilit:
- Rheumatoid arthritisThe Lancet, 2016
- Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challengesActa Pharmaceutica Sinica B, 2016
- Exosomes and Their Therapeutic Potentials of Stem CellsStem Cells International, 2015
- Immunosuppressive Exosomes: A New Approach for Treating ArthritisInternational Journal of Rheumatology, 2012
- 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiativeAnnals of the Rheumatic Diseases, 2010
- Effective Treatment of Inflammatory Disease Models with Exosomes Derived from Dendritic Cells Genetically Modified to Express IL-4The Journal of Immunology, 2007
- Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen‐induced arthritisArthritis & Rheumatism, 2004
- Distinct roles for the NF-κB1 (p50) and c-Rel transcription factors in inflammatory arthritisJournal of Clinical Investigation, 2000
- Genetic approaches in mice to understand Rel/NF-κB and IκB function: transgenics and knockoutsOncogene, 1999
- NF-κB activation provides the potential link between inflammation and hyperplasia in the arthritic jointProceedings of the National Academy of Sciences, 1998